Accessibility StatementSkip Navigation NEW YORK, Oct. 28, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Baxter International, Inc. ("Baxter International, Inc." or the "Company") (NYSE: BAX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Baxter International, Inc. investors who were adversely affected by alleged securities fraud between February 23, 2022 and July 30, 2025. Follow the link below to get more information and be contac ...

Core Viewpoint - A class action lawsuit has been filed against Baxter International Inc. and certain senior executives for securities fraud following a significant stock drop due to potential violations of federal securities laws [1][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Northern District of Illinois, captioned Electrical Workers Pension Fund, Local 103, I.B.E.W. v. Baxter International Inc., et al., No. 1:25-cv-12672 [3]. - Investors have until December 15, 2025, to request to lead the case [3]. Group 2: Product Issues - Baxter's Novum IQ Large Volume pump, a key growth driver, faced serious malfunctions after its launch in Canada, including under-infusion and over-infusion of medications [4][5]. - The company previously claimed that the Novum LVP had advanced safety features and that the Canadian rollout would help resolve any issues [5]. Group 3: Stock Impact - On July 31, 2025, Baxter announced a voluntary pause on shipments and installations of the Novum LVP, leading to a stock price drop of $6.29 per share, or over 22%, from $28.05 to $21.76 [6].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Baxter International Inc. common stock during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1][3]. Group 1: Class Action Details - Investors who bought Baxter common stock between February 23, 2022, and July 30, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by December 15, 2025 [3]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own success in recovering significant amounts for investors [4]. - The firm has been recognized for its achievements, including being ranked No. 1 for securities class action settlements in 2017 and securing over $438 million for investors in 2019 [4]. Group 3: Case Allegations - The lawsuit alleges that Baxter misled investors by failing to disclose systemic defects in the Novum IQ Large Volume Pump, which led to serious risks for patients [5]. - Specific claims include that Baxter was aware of multiple malfunctions and injuries related to the device but did not take adequate remedial measures, resulting in misleading statements about the product's safety and efficacy [5].

Core Viewpoint - Class actions have been initiated on behalf of stockholders of Baxter International, Spirit Aviation Holdings, and Molina Healthcare, with specific allegations of misleading statements and undisclosed risks during designated class periods [1]. Baxter International, Inc. (NYSE:BAX) - Class Period: February 23, 2022 to July 30, 2025 - Lead Plaintiff Deadline: December 15, 2025 - Allegations include systemic defects in the Novum LVP leading to malfunctions that posed serious risks to patients, inadequate remedial measures by Baxter, and misleading statements regarding the safety and efficacy of the product [5]. Spirit Aviation Holdings, Inc. (OTCMKTS:FLYYQ) - Class Period: May 28, 2025 to August 29, 2025 - Lead Plaintiff Deadline: December 1, 2025 - Allegations state that Spirit failed to disclose substantial risks of financial instability and potential bankruptcy, leading to a significant drop in stock price after the announcement of Chapter 11 filing [5]. Molina Healthcare, Inc. (NYSE:MOH) - Class Period: February 5, 2025 to July 23, 2025 - Lead Plaintiff Deadline: December 2, 2025 - Allegations include failure to disclose adverse facts regarding medical cost trends and misleading statements about the company's growth prospects, which could lead to a reduction in financial guidance for fiscal year 2025 [6].

Core Viewpoint - A securities fraud class action lawsuit has been filed against Baxter International, Inc. for misleading investors regarding the safety and operational issues of its Novum IQ Large Volume Pump, leading to significant financial losses for shareholders [1][5]. Summary by Sections Lawsuit Announcement - Glancy Prongay & Murray LLP has announced a class action lawsuit on behalf of Baxter investors who purchased shares between February 23, 2022, and July 30, 2025, with a deadline of December 15, 2025, for filing a lead plaintiff motion [1]. Safety Issues and Stock Impact - Reports surfaced on April 7, 2025, regarding serious safety issues with Baxter's Novum LVP, leading to its removal from a hospital system due to claims that the pumps were unsafe [2]. - Baxter issued warning letters about underinfusion risks on April 24, 2025, and later revealed 79 reports of serious injuries and two patient deaths related to the device, prompting a Class I recall from the FDA [3]. - Following the announcement of a pause in shipments and installations of the Novum LVP on July 31, 2025, Baxter's stock price dropped by $6.24, or 22.4%, closing at $21.61 per share [4]. Allegations in the Lawsuit - The lawsuit alleges that Baxter made materially false and misleading statements and failed to disclose critical information about the Novum LVP's systemic defects, which posed risks of serious injury or death to patients [5][6]. - Specific allegations include the company's knowledge of device malfunctions, inadequate remedial measures, and the risk of halting new sales of the Novum LVP due to safety concerns [5][6].

NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP: Do you, or did you, own shares of Baxter International Inc. (NYSE: BAX)?Did you purchase your shares between February 23, 2022 and July 30, 2025, inclusive?Did you lose money in your investment in Baxter International Inc.?Do you want to discuss your rights? Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Baxter International Inc. (“Baxter” or the “Company”) (NYSE: BAX) investors of an upcoming deadline invo ...

Core Viewpoint - Baxter International, Inc. is facing a class action lawsuit due to allegations of issuing false and misleading statements regarding the safety and efficacy of its Novum LVP product, which reportedly has systemic defects leading to serious patient risks [2]. Summary by Sections Allegations - The lawsuit claims that Baxter's Novum LVP product experienced systemic defects causing malfunctions such as underinfusion, overinfusion, and complete non-delivery of fluids, posing risks of serious injury or death to patients [2]. - Baxter was allegedly aware of multiple device malfunctions, injuries, and deaths related to these defects but failed to adequately address them [2]. - The company's attempts to mitigate these issues through customer alerts were deemed insufficient, as design flaws persisted [2]. - There was a heightened risk that customers would be instructed to take existing Novum LVPs out of service, and Baxter would halt all new sales of these pumps [2]. - Baxter's statements regarding the safety, efficacy, product rollout, customer feedback, and sales prospects of the Novum LVPs were claimed to be materially false and misleading [2]. Class Action Details - The class period for the lawsuit is defined as February 23, 2022, to July 30, 2025 [2]. - Shareholders are encouraged to register for the class action by December 15, 2025, to potentially be appointed as lead plaintiffs [3]. - Registration allows shareholders to receive updates throughout the lifecycle of the case [3]. Law Firm Information - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [4]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [4].

Core Viewpoint - The lawsuit claims that the defendants made false statements regarding Baxter's business and prospects, leading to the stock being traded at inflated prices [1] Group 1 - The lawsuit alleges that the defendants issued misleading information about Baxter's business [1] - The false statements are said to have resulted in inflated stock prices for Baxter [1]

Core Insights - Baxter International Inc. is a global healthcare technology company with a market cap of $11.8 billion, specializing in essential hospital and renal-care products [1] - The company is expected to announce its fiscal third-quarter earnings on October 30, with analysts predicting a profit of $0.60 per share, a 25% decrease from the previous year's $0.80 per share [2] - Analysts forecast an EPS of $2.45 for the current year, representing a 29.6% increase from $1.89 in fiscal 2024, and a further rise to $2.60 in FY2026 [3] Stock Performance - BAX stock has declined by 37.3% over the past year, underperforming the S&P 500 Index's 16.9% gain and the Health Care Select Sector SPDR Fund's 2.3% dip [4] - Recent pressures on BAX shares include a 3% drop on October 10 due to market-wide sell-offs linked to trade tensions with China [5] - A 3.7% decline occurred on September 25 following a U.S. Commerce Department investigation into medical equipment imports, raising concerns about potential tariffs and supply chain disruptions [6] Analyst Ratings - The consensus opinion on BAX stock is neutral, with an overall "Hold" rating from 16 analysts: three recommend "Strong Buy," twelve suggest "Hold," and one advises "Moderate Sell" [7] - The average analyst price target for BAX is $27.71, indicating a potential upside of 20.4% from current levels [7]

Core Viewpoint - The Baxter International, Inc. is facing a class action lawsuit due to allegations of misleading statements and systemic defects in its Novum IQ Large Volume Pump, which have resulted in significant patient risks and a notable decline in stock price [3][4]. Group 1: Class Action Lawsuit Details - The class action lawsuit is titled "Electrical Workers Pension Fund, Local 103, I.B.E.W. v. Baxter International, Inc." and covers purchasers of Baxter common stock from February 23, 2022, to July 30, 2025 [1]. - Investors have until December 15, 2025, to seek appointment as lead plaintiff in the lawsuit [1]. - The lawsuit alleges that Baxter and its executives violated the Securities Exchange Act of 1934 by making false statements and failing to disclose critical information regarding the Novum LVP [3]. Group 2: Allegations Against Baxter - The lawsuit claims that the Novum LVP had systemic defects leading to malfunctions such as underinfusion and overinfusion, posing serious risks to patients [3]. - Baxter was reportedly aware of multiple device malfunctions and injuries but did not take adequate remedial measures [3]. - On July 31, 2025, Baxter announced a voluntary pause in shipments and installations of the Novum LVP, which led to a more than 22% drop in the company's stock price [4]. Group 3: Legal Process and Firm Background - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased Baxter common stock during the class period to seek lead plaintiff status [5]. - Robbins Geller Rudman & Dowd LLP is a leading firm in securities fraud and shareholder litigation, having recovered over $2.5 billion for investors in 2024 alone [6].